Condition: Recurrent Prostate Cancer · Sponsor: Swiss Cancer Institute
TerbinaPro is a phase II drug-repurposing study evaluating oral Terbinafine in patients with biochemical recurrence of prostate cancer after prior local treatment with curative intent. When local salvage strategies have been exhausted, recurrence usually reflects micro-metastatic disease without clearly visible metastases on imaging. Standard therapy with androgen deprivation or androgen-receptor pathway inhibitors can effectively control disease but is associated with substantial side effects and negative impact on quality of life. Terbinafine is a long-licensed, generic antifungal drug that inhibits squalene epoxidase (SQLE), an enzyme that may play a role in prostate cancer progression. Preclinical and limited clinical data suggest potential anti-cancer activity.
This description comes directly from the study's public registry record.
Stefanie Röthlisberger, PhD · +41 31 389 91 91 · trials@swisscancerinstitute.ch
Always discuss trial participation with your own doctor first.
| Kantonsspital Baden | Baden, Switzerland | Recruiting |
| Universitätsspital Basel | Basel, Switzerland | Recruiting |
| EOC - Istituto Oncologico della Svizzera Italiana | Bellinzona, Switzerland | Recruiting |
| Kantonsspital Graubünden | Chur, Switzerland | Recruiting |
| Spital Thurgau AG | Frauenfeld, Switzerland | Recruiting |
| Hôpitaux Universitaires Genève HUG | Geneva, Switzerland | Recruiting |
| Luzerner Kantonsspital | Lucerne, Switzerland | Recruiting |
| TBZO Tumor- und BrustZentrum Ostschweiz - Rapperswil | Rapperswil, Switzerland | Recruiting |
| HOCH Health Ostschweiz - Kantonsspital St. Gallen | Sankt Gallen, Switzerland | Recruiting |
| Kantonsspital Winterthur | Winterthur, Switzerland | Recruiting |
| Universitätsspital Zürich USZ | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07365423